Drug discovery

Two scientists working in a research laboratory
#Career #Drug discovery #Funding #National Institute for Health and Care Research

Over £37m funding to boost early career researchers in the UK

The National Institute for Health and Care Research (NIHR) is awarding £37 ($49) million in funding to medical research charities to support early career researchers.  It is hoped that the scheme, in partnership with the Association of Medical Research Charities (AMRC), will help medical research charities continue… Read More

#News

Biosafety testing
#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Webinar: How can a single, comprehensive test enable broader viral detection?

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

#Automated workflows #Automation #Drug discovery #Orchestration #Thermo Fisher Scientific #Webinar

The orchestrated lab: Moving beyond siloed automation

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across the… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#Webinars

Cancer tumour
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking sensitivity and resistance to Pan-RAS(ON) inhibition with KRAS

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Artificial intelligence (AI) #Computational chemistry #Drug discovery #Machine learning

AI can’t replace scientists, but here’s how it can assist them

Dr Paul Finn, Chief Scientific Officer at Oxford Drug Design, explores the current use of AI in drug discovery and where the technology falls short.  Nobody can have failed to notice the rapid entry of AI into many aspects of our daily lives; as a source of information and news,… Read More

#Exclusive Content

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Webinar: Decoding sensitivity and resistance to Pan-RAS(ON) inhibition

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Drug discovery #Fragment-based drug discovery #Hit to lead #Webinar

Accelerating hit discovery for hard-to-target proteins: A fragment library approach applied to MyD88

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

Webinar date:
Supported by BioDuro and ChemPass
#Webinars

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived Tumour Models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

Webinar date:
Supported by Champions Oncology
#Webinars

#Drug discovery #Fragment-based drug discovery #Webinar

Webinar: Accelerating hit discovery for hard-to-target proteins

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

#News

#Assays #Clinical pharmacology #Drug discovery #Live cell analysis #Polypharmacologic

How a framework of living cells can inform drug discovery

DDW Editor Reece Armstrong speaks to Yerem Yeghiazarians, CEO and Co-Founder of Soley Therapeutics, about the limitations of current assays and how the company’s live cell approach can improve drug discovery.   RA: What are the current limitations of static assays and single endpoints in assessing how cells respond to drugs? YY: Most conventional assays provide a… Read More

#Exclusive Content

#AI #Assays #Drug discovery #Lab automation #STEM

How to improve lab education

Dr Tim Meyer, Research Group Leader Pharmaceutical Biotechnology at University Medical Center Göttingen, explains why the next generation of scientists must be trained differently for the lab.   Academic life science research has traditionally been optimised for novelty. Students and early-career researchers are trained to design elegant proof-of-concept experiments, execute them manually,… Read More

#Exclusive Content #Opinion

Antibodies
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Meet the challenges of a shifting antibody discovery landscape

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benching
#News

Illustration of a virus
#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Watch now: Overcome the bottlenecks in AVA testing

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News